Theravance Biopharma (NASDAQ:TBPH) Lowered to Buy at BidaskClub
Other equities research analysts have also issued research reports about the company. HC Wainwright boosted their price objective on Theravance Biopharma from $25.00 to $30.00 and gave the stock a buy rating in a research report on Wednesday, January 8th. Piper Jaffray Companies reduced their price objective on Theravance Biopharma from $55.00 to $40.00 and set an overweight rating on the stock in a research report on Wednesday, November 6th. Robert W. Baird upgraded Theravance Biopharma from an underperform rating to a neutral rating and reduced their price objective for the stock from $22.00 to $18.00 in a research report on Wednesday, November 6th. Finally, ValuEngine lowered Theravance Biopharma from a buy rating to a hold rating in a research report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $35.75.
TBPH stock traded down $0.03 during midday trading on Thursday, reaching $25.08. 483,670 shares of the stock were exchanged, compared to its average volume of 440,405. The stock has a market capitalization of $1.42 billion, a PE ratio of -6.25 and a beta of 1.92. Theravance Biopharma has a 52 week low of $15.18 and a 52 week high of $31.54. The company has a fifty day moving average price of $26.35 and a 200 day moving average price of $21.67.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Featured Article: Portfolio Manager
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.